期刊文献+

原发性舍格伦综合征患者唇腺组织中IFN-α的表达 被引量:2

Expression of interferon-alpha in primary sjogren's syndrome
下载PDF
导出
摘要 目的检测原发性舍格伦综合征(pSS)患者唇腺中干扰素(IFN)-α的表达水平,探讨其在pSS发病机制产生的作用。方法对41例pSS患者和32例非pSS患者的唇腺组织进行IFN-α免疫组化染色,比较分析其在两组之间的差异。结果对IFN-α检测后发现,41例pSS患者中,32例表达阳性,阳性率78.05%;32例非pSS患者中4例表达阳性,阳性率2.5%。两组之间差异有显著性(P<0.05)。结论 IFN-α在pSS患者唇腺组织中存在异常表达,可能与其发病机制相关。 Objective To investigate the interferon-α levels in the labial glands of patients with primary Sjogren's syndrome(pSS),and explore the etiopathogenesis between pSS and interferon-α.Methods Immunohistochemistry was used to examine interferon-αpositive cells in labial glands in 41 patients with pSS and 32 patients with non-pSS.SAS 6.12 software package was used for student's t test.Results The positive expressions of interferon-α cells in the labial glands were found in 22 of 41 patients(78.05%) with pSS.The positive expressions of interferon-α cells in the labial glands were detected in 4 of 32 patients(2.5%) with non-pSS.There was significant difference between pSS and non-pSS.Conclusion The study revealed that the expression of interferon-α in the labial glands of patients with pSS were abnormal.It may be related with pathogenesis of primary Sjogren's syndrome.
出处 《临床和实验医学杂志》 2013年第11期817-818,821,共3页 Journal of Clinical and Experimental Medicine
基金 新疆医科大学第一附属医院青年基金(2010GXB07) 国家自然科学基金项目(10802054 11262020) 新疆维吾尔自治区自然科学基金项目(201233146-9)资助
关键词 原发性舍格伦综合征 唇腺 干扰素-Α 免疫组织化学 Primary Sjogren's syndrome Labial gland Interferon-α Immunohistochemistry
  • 相关文献

参考文献10

  • 1Fox RI. Sjsgren's syndrome[J]. Lancet, 2005,366(9482) :321 -331. 被引量:1
  • 2Venables PJ. Sjogren's syndrome[J]. Best Pract Res Clin Rheumatol, 2004,18(3) :313 -329. 被引量:1
  • 3Sugai S. Hepatitis C virus and Sjogren's syndrome[ J]. Intern Med, 2005,44(6) :533 -535. 被引量:1
  • 4Youinou P, Pets JO, Saraux A, et al. Viruses contribute to the development of Sjogren's syndrome[J]. Clin Exp Immunol, 2005,141 ( 1 ) : 19 -20. 被引量:1
  • 5Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by theAmerican- European Consensus Group [ J ]. Ann Rheum Dis, 2002,61(6) :554 -558. 被引量:1
  • 6Yamada S, Mori K, Matsuo K, et al. Interferon alfa treatment for Sjogren's syndrome associated neuropathy[J]. J Neurol Neurosurg Psychiatry, 2005,76(4) :576 -578. 被引量:1
  • 7Lavie F, Miceli - Richard C, Ittah M, et al. B - cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome[J]. Scand J Immunol, 2008,67(2) :185 - 192. 被引量:1
  • 8Hu S, Wang J, Meijer J, et al. Salivary proteomie and genomic biomar- kers for primary Sjogren's syndrome [ J ]. Arthritis Rheum, 2007,56 (11) :3588 -3600. 被引量:1
  • 9Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism[J]. Arthritis Rheum, 2005,52(4) :1185 - 1195. 被引量:1
  • 10Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon - alpha pathway activation in patients with Sjogren's syndrome treated with etanercept[J]. Arthritis Rheum, 2007,56(12) :3995 -4004. 被引量:1

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部